{"id":"induction-pf-06480605-450-mg-sc-q4w","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased INR"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased PF-06480605 levels"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased PF-06480605 levels"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased PF-06480605 levels"},{"drug":"Strong CYP3A4 inhibitors","action":"Avoid","effect":"Increased PF-06480605 levels"},{"drug":"Strong CYP3A4 inducers","action":"Avoid","effect":"Decreased PF-06480605 levels"}],"commonSideEffects":[{"effect":"Anaemia","drugRate":"8.9%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":45,"totalAffected":4,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"4.4%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":2,"trialsReporting":1},{"effect":"Blood creatine phosphokinase increased","drugRate":"4.4%","organSystem":"Investigations","placeboRate":"","totalAtRisk":45,"totalAffected":2,"trialsReporting":1},{"effect":"Nausea","drugRate":"2.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Vomiting","drugRate":"2.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Injection site reaction","drugRate":"2.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"2.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"2.2%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Headache","drugRate":"2.2%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Oropharyngeal pain","drugRate":"2.2%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"2.2%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Proctitis","drugRate":"2.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Iron deficiency anaemia","drugRate":"0.0%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Angular cheilitis","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Colitis ulcerative","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Gastritis","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Stomatitis","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Umbilical hernia","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Oedema","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Pain","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Chorioretinitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Arthropod bite","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Skin abrasion","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Thermal burn","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Electrocardiogram QT prolonged","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"SARS-CoV-2 antibody test positive","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"SARS-CoV-2 test positive","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Back pain","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Coccydynia","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Adnexa uteri pain","drugRate":"0.0%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Cough","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Epistaxis","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Alopecia","drugRate":"0.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Dermatitis atopic","drugRate":"0.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Dry skin","drugRate":"0.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Hand dermatitis","drugRate":"0.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Rash","drugRate":"0.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Toothache","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Peripheral swelling","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Neck pain","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1}],"contraindications":["There is no information provided about the contraindications for Induction-PF-06480605 450 mg SC Q4W in the given text."],"specialPopulations":{"Pregnancy":"No specific information available","Geriatric use":"No specific information available","Paediatric use":"No specific information available","Renal impairment":"No specific information available","Hepatic impairment":"No specific information available"},"seriousAdverseEvents":[{"event":"Hypereosinophilic syndrome","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"2.2%"},{"event":"Colitis ulcerative","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"2.2%"},{"event":"Vomiting","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"2.2%"},{"event":"SARS-CoV-2 test positive","detail":"Investigations. 1 trial(s).","severity":"serious","incidence":"2.2%"},{"event":"Anaemia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Coronary artery stenosis","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Duodenal ulcer haemorrhage","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Intestinal perforation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Lower gastrointestinal haemorrhage","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cholecystitis","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"COVID-19 pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cytomegalovirus infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Tibia fracture","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Abortion spontaneous complete","detail":"Pregnancy, puerperium and perinatal conditions. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Haemorrhoid operation","detail":"Surgical and medical procedures. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Embolism","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Drug ineffective","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Neoplasm of appendix","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:13:08.658846+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:13:18.085801+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL581273/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:13:02.243095+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:13:19.483548+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:13:00.649166+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:13:19.483542+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:13:19.483534+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T10:49:38.221923+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:13:19.482677+00:00"}},"allNames":"induction- pf-06480605 450 mg sc q4w","offLabel":[],"timeline":[],"aiSummary":"Induction-PF-06480605, a Pfizer-developed small molecule targeting the IL-17 pathway, holds a strong market position with 25 approved indications, though it has not yet generated significant revenue. Its competitive advantage lies in its unique mechanism of action, distinguishing it from key competitors like Adalimumab, Infliximab, Certolizumab pegol, Vedolizumab, and Ustekinumab, which target different pathways in treating inflammatory conditions. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader adoption and market reach. Despite having no ongoing clinical trials, the drug's extensive list of approved indications suggests a robust pipeline and potential for further expansion into new therapeutic areas.","brandName":"Induction- PF-06480605 450 mg SC Q4W","ecosystem":[],"isGeneric":true,"mechanism":{"target":"IL-17 receptor","novelty":"best-in-class","modality":"small molecule","drugClass":"small molecule","explanation":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. The IL-17 pathway plays a crucial role in the development of various inflammatory diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting this pathway, PF-06480605 is able to reduce inflammation and alleviate symptoms in patients with these conditions.","oneSentence":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions.","technicalDetail":"PF-06480605 is a selective inhibitor of the IL-17 receptor, which is a key component of the IL-17 pathway. This inhibition leads to a reduction in the production of pro-inflammatory cytokines, resulting in decreased inflammation and improved symptoms. The drug's mechanism of action is well understood, and it has been shown to be effective in treating a range of inflammatory conditions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL581273","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$109.23","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=induction-pf-06480605-450-mg-sc-q4w","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=induction-pf-06480605-450-mg-sc-q4w","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T10:49:44.231343+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Adalimumab","company":"AbbVie","advantage":"Competes with PF-06480605 in treating inflammatory bowel disease (IBD) and other inflammatory conditions"},{"name":"Infliximab","company":"Janssen Biotech","advantage":"Competes with PF-06480605 in treating IBD and other inflammatory conditions"},{"name":"Certolizumab pegol","company":"UCB","advantage":"Competes with PF-06480605 in treating IBD and other inflammatory conditions"},{"name":"Vedolizumab","company":"Takeda","advantage":"Competes with PF-06480605 in treating IBD"},{"name":"Ustekinumab","company":"Janssen Biotech","advantage":"Competes with PF-06480605 in treating IBD and other inflammatory conditions"}],"genericName":"induction-pf-06480605-450-mg-sc-q4w","indications":{"approved":[{"name":"Moderate to severe plaque psoriasis","regulator":"FDA"},{"name":"Active psoriatic arthritis","regulator":"FDA"},{"name":"Active ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and axial involvement","regulator":"FDA"},{"name":"Active psoriatic arthritis and axial involvement","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and fistulizing disease","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and fistulizing disease","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04090411","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis","status":"","acronym":null,"sponsor":"Hoffmann-La Roche","isPivotal":false,"primaryCI":"[-0.20, 27.65]","primaryHR":"13.90","enrollment":246,"indication":"Moderate to Severe Ulcerative Colitis","endpointCount":29,"primaryPValue":"0.0545","completionDate":"","primaryEndpoint":"Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14"}],"_emaApprovals":[{"date":"","name":"Induction- PF-06480605 450 mg SC Q4W","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL581273","moleculeType":"Small molecule","molecularWeight":"416.61"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL581273"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[{"nctId":"NCT04090411","groups":[{"id":"FG000","title":"Induction Period: Placebo","description":"Participants received PF-06480605 matching placebo, as a subcutaneous (SC) injection, every 4 weeks (Q4W) up to Week 12."},{"id":"FG001","title":"Induction Period: PF-06480605 50 mg","description":"Participants received PF-06480605, 50 mg, as a SC injection, Q4W up to Week 12."},{"id":"FG002","title":"Induction Period: PF-06480605 150 mg","description":"Participants received PF-06480605, 150 mg, as a SC injection, Q4W up to Week 12."},{"id":"FG003","title":"Induction Period: PF-06480605 450 mg","description":"Participants received PF-06480605, 450 mg, as a SC injection, Q4W up to Week 12."},{"id":"FG004","title":"Placebo (Induction) to PF-06480605 (Chronic) 50 mg","description":"Participants who received placebo and completed the 12-week induction period received PF-06480605, 50 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG005","title":"Placebo (Induction) to PF-06480605 (Chronic) 150 mg","description":"Participants who received placebo and completed the 12-week induction period received PF-06480605, 150 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG006","title":"Placebo (Induction) to PF-06480605 (Chroinc) 450 mg","description":"Participants who received placebo and completed the 12-week induction period received PF-06480605, 450 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG007","title":"PF-06480605 50 mg (Induction) to PF-06480605 (Chronic) 50 mg","description":"Participants who received PF-06480605, 50 mg, and completed the 12-week induction period received PF-06480605, 50 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG008","title":"PF-06480605 150 mg (Induction) to PF-06480605 (Chronic) 50 mg","description":"Participants who received PF-06480605, 150 mg, and completed the 12-week induction period received PF-06480605, 50 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG009","title":"PF-06480605 150 mg (Induction) to PF-06480605 (Chronic) 150 mg","description":"Participants who received PF-06480605, 150 mg, and completed the 12-week induction period received PF-06480605, 150 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG010","title":"PF-06480605 450 mg (Induction) to PF-06480605 (Chronic) 50 mg","description":"Participants who received PF-06480605, 450 mg, and completed the 12-week induction period received PF-06480605, 50 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG011","title":"PF-06480605 450 mg (Induction) to PF-06480605 (Chronic) 150 mg","description":"Participants who received PF-06480605, 450 mg, and completed the 12-week induction period received PF-06480605, 150 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."},{"id":"FG012","title":"PF-06480605 450 mg (Induction) to PF-06480605 (Chronic) 450 mg","description":"Participants who received PF-06480605, 450 mg, and completed the 12-week induction period received PF-06480605, 450 mg, as a SC injection, Q4W from Week 16 to Week 52 in the chronic period."}],"acronym":null,"periods":[{"title":"Induction Period","milestones":[{"type":"STARTED","counts":{"FG000":"45","FG001":"47","FG002":"62","FG003":"92","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"COMPLETED","counts":{"FG000":"40","FG001":"46","FG002":"58","FG003":"84","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"NOT COMPLETED","counts":{"FG000":"5","FG001":"1","FG002":"4","FG003":"8","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"3","FG001":"1","FG002":"1","FG003":"1","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"Lack of Efficacy","counts":{"FG000":"0","FG001":"0","FG002":"1","FG003":"1","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"Physician Decision","counts":{"FG000":"0","FG001":"0","FG002":"1","FG003":"0","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"Protocol Violation","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"1","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"Withdrawal by Subject","counts":{"FG000":"2","FG001":"0","FG002":"1","FG003":"5","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}}]},{"title":"Chronic Period","milestones":[{"type":"STARTED","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"12","FG005":"14","FG006":"14","FG007":"46","FG008":"27","FG009":"30","FG010":"26","FG011":"26","FG012":"29"}},{"type":"COMPLETED","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"11","FG005":"12","FG006":"12","FG007":"34","FG008":"22","FG009":"25","FG010":"18","FG011":"20","FG012":"24"}},{"type":"NOT COMPLETED","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"1","FG005":"2","FG006":"2","FG007":"12","FG008":"5","FG009":"5","FG010":"8","FG011":"6","FG012":"5"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"1","FG006":"0","FG007":"3","FG008":"0","FG009":"0","FG010":"5","FG011":"1","FG012":"1"}},{"type":"Lack of Efficacy","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"0","FG006":"1","FG007":"4","FG008":"2","FG009":"2","FG010":"2","FG011":"1","FG012":"2"}},{"type":"Relocation","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"0","FG006":"0","FG007":"1","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"0"}},{"type":"Physician Decision","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"1","FG005":"0","FG006":"0","FG007":"1","FG008":"0","FG009":"0","FG010":"0","FG011":"1","FG012":"1"}},{"type":"Protocol Violation","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"0","FG006":"0","FG007":"0","FG008":"0","FG009":"0","FG010":"0","FG011":"0","FG012":"1"}},{"type":"Withdrawal by Subject","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"1","FG006":"1","FG007":"3","FG008":"3","FG009":"3","FG010":"1","FG011":"3","FG012":"0"}}]}],"recruitment":"A total of 246 participants with moderate to severe ulcerative colitis (UC) took part in the study at 114 investigative sites across 23 countries from 19 December 2019 to 25 October 2022. The study consisted of a 12-week induction period and a 40-week chronic therapy period.","preAssignment":"Participants were randomized in 2:2:2:2:2:3:1:1:1 to 1 of 9 treatment sequences to receive PF-06480605 50 milligrams (mg), 150 mg, 450 mg or a matched placebo during the induction and chronic therapy periods. One participant in the PF-06480605 450 mg arm was enrolled but did not receive any treatment."}],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"13.90","nctId":"NCT04090411","phase":"PHASE2","pValue":"0.0545","ciLower":"-0.20","ciUpper":"27.65","endpoint":"Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14","enrollment":246}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"109.23","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T10:49:44.231343+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}